重组人干扰素肌注与干扰素阴道栓联合使用治疗宫颈高危型HPV感染临床研究

The combined use of recombinant human interferon and interferon vaginal suppository in the treatment of cervical high-risk HPV infection

目的探究重组人干扰素肌注与干扰素阴道栓联合使用治疗宫颈高危型HPV（人乳头瘤状病毒）感染临床效果。方法选取2014年1月-2015年12月来我院治疗的宫颈高危型HPV感染患者86例,随机分为甲乙两组,各组43例。给予甲组患者重组人干扰素肌注与干扰素阴道栓联合治疗,乙组患者不使用药物治疗。对比观察两组患者临床效果。结果甲组患者HPVDNA转阴率明显高于乙组,差异具有统计学意义（P〈0.05）。结论给予宫颈高危型HPV感染患者重组人干扰素肌注与干扰素阴道栓联合治疗,能显著提高疗效,值得临床推广。

Objective Exploration of recombinant human interferon intramuscular injection and interferon vaginal suppository combined therapy for cervical high-risk HPV （human papilloma virus） infections clinical effect.Methods Selected 86 cases in January 2014 to December 2015 in our hospital treatment of cervical high-risk HPV infection patients, randomly divided into two groups, each group of 43 cases.Group A were given intramuscular injection of recombinant human interferon and interferon suppository combined therapy, group B patients were not treated with interferon.The clinical effects and adverse reactions of the two groups were compared and observed.Results The group of patients with HPVDNA negative rate is significantly higher than that in group B,the difference is statistically signifcant（P〈0.05）.Conclusion Given cervical high risk HPV infection with recombinant human interferon intramuscular injection and interferon suppository of combination therapy, can signifcantly improve the therapeutic effect, and less adverse reaction, safe and effective, worthy of clinical promotion.